Wen YG, Shang DW, Xie HZ, Wang XP, Ni XJ, Zhang M, et al. (March 2013). "Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake". Human Psychopharmacology. 28 (2): 134–141. doi:10.1002/hup.2290. PMID23417765. S2CID12623938.
Kishi T, Matsuda Y, Nakamura H, Iwata N (February 2013). "Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials". Journal of Psychiatric Research. 47 (2): 149–154. doi:10.1016/j.jpsychires.2012.10.011. PMID23131856.
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU (2013). "Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics". Clinical Neuropharmacology. 36 (6): 223–238. doi:10.1097/wnf.0b013e3182aa38c4. PMID24201235. S2CID21426260.
Tenjin T, Miyamoto S, Miyake N, Ogino S, Kitajima R, Ojima K, et al. (January 2012). "Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia". Human Psychopharmacology. 27 (1): 90–100. doi:10.1002/hup.1276. PMID22278973. S2CID205925034. (Retracted, see doi:10.1002/hup.2622, PMID28657182, Retraction Watch. If this is an intentional citation to a retracted paper, please replace {{retracted|...}} with {{retracted|...|intentional=yes}}.)
Ochi T, Sakamoto M, Minamida A, Suzuki K, Ueda T, Une T, et al. (February 2005). "Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent". Bioorganic & Medicinal Chemistry Letters. 15 (4): 1055–1059. doi:10.1016/j.bmcl.2004.12.028. PMID15686911.
Nagai T, Noda Y, Une T, Furukawa K, Furukawa H, Kan QM, Nabeshima T (February 2003). "Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice". NeuroReport. 14 (2): 269–272. doi:10.1097/00001756-200302100-00023. PMID12598744. S2CID41717348.
Chen X, Wang H, Jiang J, Chen R, Zhou Y, Zhong W, et al. (March 2014). "The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses". Clinical Drug Investigation. 34 (3): 213–222. doi:10.1007/s40261-013-0167-9. PMID24399453. S2CID35831132.
Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, et al. (April 2013). "Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia". Journal of Clinical Psychopharmacology. 33 (2): 162–169. doi:10.1097/jcp.0b013e3182825bce. PMID23422369. S2CID33775568.
nih.gov
pubmed.ncbi.nlm.nih.gov
Wen YG, Shang DW, Xie HZ, Wang XP, Ni XJ, Zhang M, et al. (March 2013). "Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake". Human Psychopharmacology. 28 (2): 134–141. doi:10.1002/hup.2290. PMID23417765. S2CID12623938.
Heading CE (November 1998). "AD-5423 Dainippon Pharmaceutical Co Ltd". IDrugs. 1 (7): 813–817. PMID18465651.
Kishi T, Matsuda Y, Nakamura H, Iwata N (February 2013). "Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials". Journal of Psychiatric Research. 47 (2): 149–154. doi:10.1016/j.jpsychires.2012.10.011. PMID23131856.
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU (2013). "Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics". Clinical Neuropharmacology. 36 (6): 223–238. doi:10.1097/wnf.0b013e3182aa38c4. PMID24201235. S2CID21426260.
Tenjin T, Miyamoto S, Miyake N, Ogino S, Kitajima R, Ojima K, et al. (January 2012). "Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia". Human Psychopharmacology. 27 (1): 90–100. doi:10.1002/hup.1276. PMID22278973. S2CID205925034. (Retracted, see doi:10.1002/hup.2622, PMID28657182, Retraction Watch. If this is an intentional citation to a retracted paper, please replace {{retracted|...}} with {{retracted|...|intentional=yes}}.)
Ochi T, Sakamoto M, Minamida A, Suzuki K, Ueda T, Une T, et al. (February 2005). "Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent". Bioorganic & Medicinal Chemistry Letters. 15 (4): 1055–1059. doi:10.1016/j.bmcl.2004.12.028. PMID15686911.
Nagai T, Noda Y, Une T, Furukawa K, Furukawa H, Kan QM, Nabeshima T (February 2003). "Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice". NeuroReport. 14 (2): 269–272. doi:10.1097/00001756-200302100-00023. PMID12598744. S2CID41717348.
Chen X, Wang H, Jiang J, Chen R, Zhou Y, Zhong W, et al. (March 2014). "The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses". Clinical Drug Investigation. 34 (3): 213–222. doi:10.1007/s40261-013-0167-9. PMID24399453. S2CID35831132.
Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, et al. (April 2013). "Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia". Journal of Clinical Psychopharmacology. 33 (2): 162–169. doi:10.1097/jcp.0b013e3182825bce. PMID23422369. S2CID33775568.
Tenjin T, Miyamoto S, Miyake N, Ogino S, Kitajima R, Ojima K, et al. (January 2012). "Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia". Human Psychopharmacology. 27 (1): 90–100. doi:10.1002/hup.1276. PMID22278973. S2CID205925034. (Retracted, see doi:10.1002/hup.2622, PMID28657182, Retraction Watch. If this is an intentional citation to a retracted paper, please replace {{retracted|...}} with {{retracted|...|intentional=yes}}.)
semanticscholar.org
api.semanticscholar.org
Wen YG, Shang DW, Xie HZ, Wang XP, Ni XJ, Zhang M, et al. (March 2013). "Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake". Human Psychopharmacology. 28 (2): 134–141. doi:10.1002/hup.2290. PMID23417765. S2CID12623938.
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU (2013). "Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics". Clinical Neuropharmacology. 36 (6): 223–238. doi:10.1097/wnf.0b013e3182aa38c4. PMID24201235. S2CID21426260.
Tenjin T, Miyamoto S, Miyake N, Ogino S, Kitajima R, Ojima K, et al. (January 2012). "Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia". Human Psychopharmacology. 27 (1): 90–100. doi:10.1002/hup.1276. PMID22278973. S2CID205925034. (Retracted, see doi:10.1002/hup.2622, PMID28657182, Retraction Watch. If this is an intentional citation to a retracted paper, please replace {{retracted|...}} with {{retracted|...|intentional=yes}}.)
Nagai T, Noda Y, Une T, Furukawa K, Furukawa H, Kan QM, Nabeshima T (February 2003). "Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice". NeuroReport. 14 (2): 269–272. doi:10.1097/00001756-200302100-00023. PMID12598744. S2CID41717348.
Chen X, Wang H, Jiang J, Chen R, Zhou Y, Zhong W, et al. (March 2014). "The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses". Clinical Drug Investigation. 34 (3): 213–222. doi:10.1007/s40261-013-0167-9. PMID24399453. S2CID35831132.
Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, et al. (April 2013). "Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia". Journal of Clinical Psychopharmacology. 33 (2): 162–169. doi:10.1097/jcp.0b013e3182825bce. PMID23422369. S2CID33775568.